-
Ceritinib (INN,
trade name
Zykadia /zaɪˈkeɪdiːə/ zy-KAY-dee-ə) is a prescription-only drug used for the
treatment of non-small cell lung
cancer (NSCLC)...
- and
targeting a
broader set of
resistance mutations. As such, Novartis'
ceritinib was
approved by the FDA in
April 2014 for
treatment of NSCLC. It provided...
- LDK may
refer to:
Ceritinib or LDK378, a drug used for the
treatment non-small cell lung
cancer L.D.K.
Lounge Designers Killer, a 2005
album by ****anese...
- ALK
inhibitors crizotinib, or its
successors alectinib, brigatinib, and
ceritinib.
Those treated with ALK
inhibitors who
relapse can then be
treated with...
-
brand name
Xalkori and
Crizalk that
targets the EML4/ALK
fusion gene.
Ceritinib is a
second generation targeted therapy (FDA
approved in 2014), manufactured...
- days of treatment.
Treatment must be
continued indefinitely at present.
Ceritinib was
approved by the FDA in
April 2014 for the
treatment of
patients with...
-
certain resistance mutations that
develop during treatment with crizotinib.
Ceritinib demonstrates clinical activity (including
treating the brain) in ROS1+...
- as
those increasing the AUC of
digoxin to ≥1.25-fold);
telithromycin ceritinib mibefradil (used for the
treatment of
hypertension and
chronic angina...
-
Sorafenib Sunitinib Tivozanib Toceranib Vandetanib ALK
Alectinib Brigatinib Ceritinib Crizotinib Ensartinib Lorlatinib RET inhibitors:
Entrectinib (ALK, ROS1...
-
crizotinib benefited from second-generation ALK
inhibitors including ceritinib,
alectinib and brigatinib.
Resistance to ALK
inhibitors can
occur with...
